Ventures

Hemeo addresses the challenge of treating ICU patients with coagulation issues by developing a decision support system. This system uses patient data and real-time monitoring to accurately assess bleeding and thrombosis risks. By modeling the coagulation system with a smart algorithm, it provides personalized recommendations to clinicians, helping them make more informed therapy decisions. With ICU patients at high risk for venous thromboembolism and bleeding incidents, this solution aims to improve patient outcomes and reduce uncertainty in treatment.

ProVascTec offers a novel solution for chronic arterial disease, focusing on peripheral arterial disease (PAD) and chronic limb ischemia. Unlike traditional treatments like angioplasty or bypass surgery, ProVascTec aims to stimulate vascular tissue growth using mesenchymal stem cells, reducing complications and improving blood flow. This innovative approach has the potential to benefit millions of patients suffering from PAD worldwide.

Porous GmbH has developed an ultrasound technology that accurately diagnoses cortical bone health, addressing the limitations of traditional methods. Osteoporosis affects millions globally, leading to frequent and costly fractures. Current diagnostics often miss early-stage bone deterioration, but Porous GmbH’s patented algorithms allow ultrasound to measure bone quality at a microscopic level for a safer and more precise method for early detection of osteoporosis, also reducing healthcare costs.

Foveo Fertility addresses the challenge of improving in vitro fertilization (IVF) success rates by providing a stable physiological environment for egg cells. Unlike current methods that expose egg cells to air, leading to cooling and evaporation, Foveo Fertility ensures consistent conditions for optimal egg cell quality. This innovation also streamlines workflow in the IVF lab, reducing human error and saving time for embryologists. With no other product on the market offering constant physiological conditions for egg cells, Foveo Fertility aims to improve the lives of both lab workers and patients by maximizing the potential for successful pregnancies.

ImplantGuard is addressing the challenge of bacterial infections post-implant surgery, which affect millions of patients worldwide. Their solution involves coating implants with antimicrobials using a versatile and cost-effective process called plasma nitriding. This innovative coating technology offers a safer and more efficient alternative to existing implant coatings, potentially reducing the risk of infections and the need for costly surgical procedures.

ChARM, or the Children’s Automated Respiration Monitor, addresses the challenge of pneumonia misdiagnosis in low-resource settings. This battery-powered device provides accurate breathing rate monitoring for children under five, empowering healthcare workers to make correct diagnoses swiftly. By streamlining the diagnostic process, ChARM facilitates timely treatment, potentially saving thousands of young lives annually.

MindAffect aims to diagnose visual and hearing impairments in over 2 billion people, including children, seniors, and the disabled, leading to untreated impairments and significant societal costs. Their innovative brain computer interface and AI technology offer a solution by analyzing brain responses to auditory or visual stimuli, reducing testing time and improving accuracy.

Lamina offers a solution for the regeneration of cartilage, addressing a prevalent issue affecting millions worldwide. Traditional treatments focus on symptom management or procedures like joint replacement, with limited success. Lamina's ARTiREG, enhances cell therapy with a special framework to hold Mesenchymal stem cells which repair for the body and help fix damaged cartilage. This patented approach promotes fast recovery, potentially transforming outcomes for individuals with cartilage damage.